Emerging Companies

Scientific American will release the third annual Worldview: A Global Biotechnology Perspective at this year’s BIO International Convention.  Created in partnership with BIO, the publication explores the diverse economic regions of the world, highlighting success stories, policy achievements, cutting-edge science and the unique challenges that lie ahead. This year’s report focuses on BRIC (Brazil, Russia, India and China) country efforts to build local biotechnology hubs. 

BIO review of this emerging science illustrates progress in applying synthetic biology to improve manufacturing processes.

Brenda Herschbach Jarrell and Jennifer Groves present an overview of the IP landscape in China, India, Brazil and Korea.

The 12th Annual BIO Investor Forum featured exciting panels, partnering meetings and more!

This backgrounder emphasizes the importance of strengthening the SBIR program to support bringing scientific innovation to the public.

The summary explains the criteria for investment companies, the process by which investment companies would apply and the manner in which the equity financing provided by the SBA could used.

The purpose of this survey was to examine technology transfer and licensing practices by biotechnology companies and determine its importance to the industry.

The Department of Energy's Assistant Secretary Cathy Zoi announced funding of $24 million for three research groups addressing key hurdles in commercialization of algae at the 2010 World Congress.

The Department of Energy's Assistant Secretary Cathy Zoi announced funding of $24 million for three research groups addressing key hurdles in commercialization of algae at the 2010 World Congress.

The U.S. bioscience industry continued to score employment gains through 2008 - the first year of the recent economic downturn, according to a study released today by Battelle and the Biotechnology Industry Organization (BIO).

Biotechnology is all around us and is already a big part of our lives, providing breakthrough products and technologies to combat disease, reduce our environmental footprint, feed the hungry, and make useful products.

The “Valley of Death” — that sketchy period between when a startup settles on a technical approach and delivers a product to market — needn’t crush an early-stage biofuels business, say officers at three companies that are making that journey now.

There may be no summer lovin’ for biotechs. By most accounts, investors will remain tightfisted with their cash for some time, opening up their wallets for only the most promising investments. In a sign of how devastating the global economic crisis has become for the industry, more than a third of the 344 public biotechs had less than six months cash on hand by the end of March 2009, according to Burrill & Company statistics. And the situation is probably even bleaker among smaller, private companies.

Letters, Testimony & Comments

April 30 2015
On behalf of the Biotechnology Industry Organization Before the United States House of Representatives Committee on Financial Services, Subcommittee on Capital Markets and Government Sponsored Enterprises --- Legislative Proposals to Enhance Capital Formation and Reduce Regulatory Burdens
April 29 2014
Chairperson Mikulski, Ranking Member Shelby, Members of the Committee, thank you for the opportunity to provide you with written testimony on the extremely important topic of driving innovation through federal investments.
November 6 2013
On behalf of the BIO and its 1,100 members, I am writing in strong support of your Start-up Jobs and Innovation Act. I want to thank you for introducing this important legislation, which will spur investment in small biotech companies and other innovative businesses.
July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.

Press Releases

August 11 2015
BIO Investor Forum to be held October 20-21 in San Francisco, California  
June 11 2015
BIO released a new report - Emerging Therapeutic Company Investment and Deal Trends – highlighting ten years (2005-2014) of biotechnology funding and deal making across five areas: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions. The report also offers a first-time look at the degree of collaboration across the industry’s clinical pipeline.
May 21 2015
By making this tax credit permanent, companies conducting their development programs will be able to estimate their tax liability and will not be burdened by the constant uncertainty regarding whether or not the R&D Tax Credit will be extended.
May 13 2015
By teaming up with Aon, we are able to offer our members state-of-the-art coverage enhancements specific for life sciences companies...
May 7 2015
Program will improve liquidity and enhance capital formation for emerging biotech companies